Design Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule gene-targeted therapies for genetic diseases driven by nucleotide-repeat expansions. Its GeneTAC platform aims to modulate disease-causing genes at the DNA level rather than replacing genes or editing the genome permanently. Lead programs have focused on conditions such as Friedreich’s ataxia and myotonic dystrophy type 1.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -19.1 | — |
| Q3 2025 | 0 | — | -17 | — |
| Q4 2025 | 0 | — | -16 | — |
| Q1 2026 | 0 | — | -17.6 | — |
| Q2 2026 | 0 | — | -20.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Daktronics, Inc. (DAKT), Evolv Technologies Holdings, Inc. (EVLV), Annexon, Inc. (ANNX), Bioventus Inc. (BVS), First Financial Corporation (THFF), ProFrac Holding Corp. (ACDC)